All In Biotech

Drug Trial Radar · NCT02507284

Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)

Last checked: Nov 19, 2026Latest source record: Jul 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

106

Actual

Start

May 10, 2016

Primary completion

Sep 10, 2018

Study completion Dec 21, 2018

Sponsor

Lead sponsor
Azevan PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS); NeuroNEXT Network
First posted
Jul 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease. Two-thirds of all participants will receive SRX246, while the other third will receive a placebo.

Conditions

  • Irritable Mood
  • Huntington's Disease

Interventions

  • SRX246Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tolerability of SRX246Time frame: 12 weeks

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • UCLA, Neurology Clinic

    Los Angeles, California

  • UC Davis Medical Center, Department of Neurology, CTSC Clinical Research Center

    Sacramento, California

  • University of Colorado Hospital Translational Research Center

    Aurora, Colorado

  • University of Miami, Miller School of Medicine, Jackson Behavioral Health Hospital

    Miami, Florida

  • Emory University

    Atlanta, Georgia

  • Northwestern Out-Patient Neurology Clinic

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Massachusetts General Hospital

    Charlestown, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • SUNY Stony Brook Clinical Research Center, Department of Neurology

    East Setauket, New York

  • Columbia University Medical Center, New York Presbyterian Hospital

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • University Medical Arts Building

    Cincinnati, Ohio

  • Ohio State University, Wexner Medical Center, Department of Neurology

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • University of Pittsburgh Medical Center, Department of Neurology

    Pittsburgh, Pennsylvania

  • Vanderbilt Clinical Research Center

    Nashville, Tennessee

  • UT Southwestern Medical Center

    Dallas, Texas

  • University of Utah, Department of Neurology

    Salt Lake City, Utah

  • University of Virginia Health System, Department of Neurology

    Charlottesville, Virginia

  • Swedish Neuroscience Institute

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.